MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

Search

Durect Corp

Geschlossen

0.65 6.56

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.61

Max

0.65

Schlüsselkennzahlen

By Trading Economics

Angestellte

20

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+681.25% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

12. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-2.5M

17M

Vorheriger Eröffnungskurs

-5.91

Vorheriger Schlusskurs

0.65

Durect Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

1. Juli 2025, 23:09 UTC

Ergebnisse

Constellation Brands 1Q Profit, Sales Decline Amid Softer Consumer Demand -- Update

1. Juli 2025, 19:16 UTC

Akquisitionen, Fusionen, Übernahmen

Sabadell Seeks Shareholder Approval of Nearly $4 Billion Sale of U.K. Unit to Santander

1. Juli 2025, 23:47 UTC

Market Talk

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

1. Juli 2025, 23:41 UTC

Market Talk

Gold Steady, Underpinned by U.S. Fiscal-Deficit Concerns -- Market Talk

1. Juli 2025, 22:23 UTC

Akquisitionen, Fusionen, Übernahmen

James Hardie: Deal Represents Implied Value of $8.4 Billion

1. Juli 2025, 22:23 UTC

Akquisitionen, Fusionen, Übernahmen

James Hardie: Cash and Stock Deal Implies $54.18 Per AZEK Share

1. Juli 2025, 22:21 UTC

Akquisitionen, Fusionen, Übernahmen

James Hardie Completes Acquisition of AZEK

1. Juli 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1. Juli 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1. Juli 2025, 20:24 UTC

Ergebnisse

Constellation Brands Earnings Miss as Consumers Cool on Alcohol -- Barrons.com

1. Juli 2025, 19:55 UTC

Market Talk

Oil Futures Resume Cautious Rally -- Market Talk

1. Juli 2025, 19:27 UTC

Market Talk

U.S. Natural Gas Futures Lose More Ground -- Market Talk

1. Juli 2025, 19:12 UTC

Market Talk

Dollar Little Changed as Tax-And-Spending Bill Advances -- Market Talk

1. Juli 2025, 19:01 UTC

Akquisitionen, Fusionen, Übernahmen

Sabadell Seeks Shareholder Approval of Nearly $4B Sale of U.K. Unit to Santander

1. Juli 2025, 18:41 UTC

Akquisitionen, Fusionen, Übernahmen

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

1. Juli 2025, 18:33 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

1. Juli 2025, 18:33 UTC

Market Talk

Gold Gains as Investors Look Ahead on Budget Bill -- Market Talk

1. Juli 2025, 18:32 UTC

Market Talk

Mexico Manufacturing PMIs Remain Weak in June -- Market Talk

1. Juli 2025, 18:22 UTC

Market Talk

Remittances to Mexico Down in May -- Market Talk

1. Juli 2025, 17:45 UTC

Market Talk

Seasonal Demand Supports Further Oil Gains -- Market Talk

1. Juli 2025, 17:01 UTC

Akquisitionen, Fusionen, Übernahmen

Danone Completed Acquisition of Majority Stake in Kate Farms

1. Juli 2025, 16:55 UTC

Ergebnisse

10 European Dividend Stocks That Could Beat Their U.S. Counterparts -- Barrons.com

1. Juli 2025, 16:27 UTC

Market Talk

Trade Concerns Ease in Bank of Mexico Survey -- Market Talk

1. Juli 2025, 16:25 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Home Depot's GMS Buy Unlocks New Vertical Adjacent to SRS -- Market Talk

1. Juli 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

1. Juli 2025, 15:48 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Home Depot's Offer for GMS Unlikely to Be Beat -- Market Talk

1. Juli 2025, 15:46 UTC

Market Talk

Global Equities Roundup: Market Talk

1. Juli 2025, 15:46 UTC

Market Talk

Amazon Seen With Improved Logistics Ahead of Longer Prime Day -- Market Talk

1. Juli 2025, 14:54 UTC

Market Talk

Thales Expected to Stick to This Year's Sales Guidance -- Market Talk

1. Juli 2025, 14:49 UTC

Market Talk

Platinum Prices Extend Rally on China Demand, Supply Worries -- Market Talk

Peer-Vergleich

Kursveränderung

Durect Corp Prognose

Kursziel

By TipRanks

681.25% Vorteil

12-Monats-Prognose

Durchschnitt 5 USD  681.25%

Hoch 5 USD

Tief 5 USD

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Durect Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

1 ratings

1

Buy

0

Halten

0

Sell

Finanzen

$

Über Durect Corp

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.